Abstract:Innate immune response provides the host with an early protection barrier against invading pathogens and helps shape the nature and quality of the subsequent adaptive immune response of the host. Ubiquitin-specific protease 18 (USP18 ) plays an important role in the host innate immune response. This role is mediated both via its enzymatic and non-enzymatic functions. First, conjugation of ISG15 to its targets is counteracted by the enzymatic activity of USP18. Second, the C terminus of USP18 can bind to the type I interferon receptor subunit (IFNAR2) and compete with JAK1 receptor binding which inhibits the activation of the receptor associated kinases JAK1 and TYK2. While USP18 deficiency prolonged phosphorylation of STATs and increased ISG expression in response to IFN, forced expression of either wild type or enzymatically inactive mutatant USP18 in the cells reduces the phosphorylation level of STATs and the downstream transcriptional events. USP18 knockout mice have a greater resistance to viral/bacterial infection in several experimental mouse models. In addition, USP18 was found to inhibit IFNsignaling but did not inhibit IFN, IFN, IL-6, or IL-12 signaling pathways. Results from our previous study demonstrated that USP18 was overexpressed in the liver biopsy specimens of HCV patients who do not respond to the combination therapy of pegylated interferon-alpha (IFN) and ribavirin (RBV). We also found that increased expression of either wild type USP18 or catalytically inactive mutant USP18 blunted the effect of both type I and type III IFNs and promoteded HCV production in the J6/JFH1 culture system. Another study suggested that HBV infection is more rapidly cleared if USP18 expression level is reduced. Most recently it has been shown that USP18 may play an important role in mediating inflammation. Inhibition of USP18 leads to upregulation of several pro-inflammatory chemokine, including CCL5, CXCL10 and IL-15, via induction of the STAT signaling pathway and increases IFN induced beta cell apoptosis. Taken together, small molecule inhibitors against USP18 might be a viable approach to potentiate the host innate immunity leading to a better control of viral infections.

[Research progress on ubiquitin-specific protease in antiviral immunity].

Ubiquitin-specific peptidase 22 in cancer

Roles of ubiquitin-specific proteases in inflammatory diseases

Advances in the Development Ubiquitin-Specific Peptidase (USP) Inhibitors

USP49 Potently Stabilizes APOBEC3G Protein by Removing Ubiquitin and Inhibits HIV-1 Replication

Deubiquitinase USP47 attenuates virus-induced type I interferon signaling

Insights Into the Properties, Biological Functions, and Regulation of USP21

Targeting ubiquitin specific proteases (USPs) in cancer immunotherapy: from basic research to preclinical application

The role of USP 18 in interferon signaling and inflammation

The Functional Deubiquitinating Enzymes in Control of Innate Antiviral Immunity

Unraveling the Immune Regulatory Functions of USP5: Implications for Disease Therapy

Advance in Research on the Regulation of Innate Immune Response by Ubiquitination

Ubiquitin-Specific Peptidase 7: A Novel Deubiquitinase That Regulates Protein Homeostasis and Cancers

Spotlight on USP4: Structure, Function, and Regulation

Role of ubiquitin specific proteases in the immune microenvironment of prostate cancer: A new direction

An Integrated View of Deubiquitinating Enzymes Involved in Type I Interferon Signaling, Host Defense and Antiviral Activities

Induction of USP25 by viral infection promotes innate antiviral responses by mediating the stabilization of TRAF3 and TRAF6

The emerging role of USP29 in cancer and other diseases

Usp19 Modulates Autophagy and Antiviral Immune Responses by Deubiquitinating Beclin-1

Cellular Deubiquitylating Enzyme: A Regulatory Factor of Antiviral Innate Immunity

Immune Evasion and Drug Resistance Mediated by USP22 in Cancer: Novel Targets and Mechanisms